SVCM
CNTA

Saturn V Capital Management’s Centessa Pharmaceuticals CNTA Stock Holding History

Saturn V Capital Management’s Portfolio CNTA Stock Details CNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-282,692
Closed -$7.07M – 22
2025
Q4 		$7.07M Sell
282,692
-451,847
-62% -$11.4M 1.3% 18
2025
Q3 		$17.8M Sell
734,539
-58,788
-7% -$1.04M 3.91% 12
2025
Q2 		$10.4M Buy
793,327
+344,635
+77% +$4.37M 4.22% 12
2025
Q1 		$6.45M Buy
+448,692
New +$7.34M 3.26% 13

Other funds holding CNTA

MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
IVLAV
Index Venture Life Associates VI St. Helier, Jersey $396M AUM 176.22% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Saturn V Capital Management's CNTA Position: Q1 2026 in Review

Saturn V Capital Management sold out of Centessa Pharmaceuticals (CNTA) in Q1 2026, closing a stake of 282,692 shares — an estimated $7.07M sold.

Saturn V Capital Management first reported a position in CNTA in Q1 2025 and held it in 4 quarters. The position peaked at $17.8M in Q3 2025. 161 funds tracked by Wall St. Rank hold CNTA as of Q1 2026.

  • Saturn V Capital Management reported no remaining Centessa Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Saturn V Capital Management sold 282,692 Centessa Pharmaceuticals shares in Q1 2026, an estimated $7.07M.
  • Saturn V Capital Management first reported a position in Centessa Pharmaceuticals in Q1 2025 and held it in 4 quarters.
  • Saturn V Capital Management's Centessa Pharmaceuticals position peaked at $17.8M in Q3 2025.
  • 161 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q1 2026.

Based on Saturn V Capital Management's 13F filing for Q1 2026, filed 15 May 2026.